ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Acute-phase reactants"

  • Abstract Number: 2813 • 2019 ACR/ARP Annual Meeting

    Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis

    Cecilia Svanberg 1, Helena Enocsson 1, Klara Martinsson 1, Lawrence Potempa 2, Ibraheem Rajab 2, Jonas Wetterö 1, Marie Larsson 1 and Christopher Sjöwall3, 1Linköping University, Linköping, Sweden, 2Roosevelt University, Chicago, IL, 3Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disease affecting multiple organs and which is characterized by autoantibodies directed against nuclear constituents. Common autoantibody…
  • Abstract Number: 908 • 2016 ACR/ARHP Annual Meeting

    Utilization of Multiple Acute Phase Proteins and Biomarkers for Giant Cell Arteritis – Insight into Diagnosis and Clinical Complications

    Blaz Burja1, Katja Lakota1, Tadeja Kuret1, Polona Žigon1, Rok Jese1, Matija Tomsic1, Ziga Rotar1, Sonja Praprotnik2, Tinka Svec1, Sašša Čučnik1, Snezna Sodin Semrl1 and Alojzija Hocevar1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia

    Background/Purpose: Giant Cell Arteritis (GCA) is considered an urgent condition in Rheumatology, due to high risk of permanent vision loss and cerebro-vascular insults. No diagnostic…
  • Abstract Number: 255 • 2015 ACR/ARHP Annual Meeting

    What Acute Phase Reactants Accurately Identify Patients Who Will Develop Amyloidosis in Familial Mediterranean Fever? a Systematic Review

    Burak Erer1, Erkan Demirkaya2, Seza Ozen3,4, Tilmann Kallinich5 and Loreto Carmona6, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Gulhane Military Medical Faculty, Ankara, Turkey, 3Pediatric Nephrology and Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 4Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 5Charite, University Medicine Berlin, Berlin, Germany, 6Instituto de Salud Musculoesqueletica, Madrid, Spain

    Background/Purpose: Familial Mediterranean Fever (FMF) is a prototype of autoinflammatory diseases. Inflammation is expressed by attacks of fever and serositis and elevation of acute phase…
  • Abstract Number: 467 • 2015 ACR/ARHP Annual Meeting

    Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values

    In Je Kim1, Hyesook Park2, Sang-Cheol Bae3 and Jisoo Lee4, 1Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, 2Dep of Preventive medicine, Ewha Womans University School of medicine, Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 4Internal Medicine, Ewha Womans Univeristy School of Medicine, Seoul, South Korea

    Background/Purpose: Despite high clinical disease activity measured by joint counts and global assessments, some patients with active rheumatoid arthritis (RA) have normal acute-phase reactant (APR)…
  • Abstract Number: 803 • 2015 ACR/ARHP Annual Meeting

    Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus?

    Lina Wirestam1, Helena Enocsson2, Christopher Sjöwall2, Thomas Skogh2, Maija-Leena Eloranta3, Lars Rönnblom3 and Jonas Wetterö2, 1Department of Clinical & Experimental Medicine, Rheumatology/AIR, Linkoping, Sweden, 2Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, 3Medical Sciences, Rheumatology clinic, Uppsala, Sweden

    Background/Purpose: The type I interferon (IFN) system is important in the pathogenesis of systemic lupus erythematosus (SLE). We have previously shown an inhibitory effect of…
  • Abstract Number: 1772 • 2015 ACR/ARHP Annual Meeting

    Anti-Pentraxin 3 Antibodies Ameliorate Disease Manifestations and Lupus-like Nephritis in New Zealand Black/New Zealand White F1 Mice

    Mariele Gatto1, Nicola Bassi1, Anna Ghirardello1, Roberto Luisetto1, Silvano Bettio1, Luca Iaccarino1, Leonardo Punzi2 and Andrea Doria2, 1Department of Medicine-DIMED, University of Padova, Padova, Italy, 2Department of Medicine - DIMED, University of Padova, Padova, Italy

     Background/Purpose: Pentraxin 3 (PTX3) is an acute-phase protein released by different cell types including renal epithelial cells and immune-competent cells. PTX3 is able to either…
  • Abstract Number: 1964 • 2015 ACR/ARHP Annual Meeting

    Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis

    Katja Lakota1, Tadeja Kuret2, Polona Žigon1, Ziga Rotar1, Matija Tomsic1, Saša Čučnik1,2, Snezna Sodin Semrl1,3 and Alojzija Hocevar1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, 3Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia

    Background/Purpose: Giant cell arteritis (GCA) is a large- and medium- vessel arteritis characterized by a range of histological patterns of vascular wall injury. The temporal…
  • Abstract Number: 2767 • 2015 ACR/ARHP Annual Meeting

    Comparative Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated By Serum Amyloid a

    Katja Lakota1, Dolores Hrušovar2, Katjusa Mrak-Poljšak3, Polona Žigon1, Saša Čučnik1,2, Borut BožiÄ�2,3, Matija Tomšič1 and Snezna Sodin Semrl1,4, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, 3University Medical Centre Ljubljana, Ljubljana, Slovenia, 4Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia

     Background/Purpose: In certain chronic diseases, such as rheumatoid arthritis (RA), atherosclerosis is more prevalent. RA patients have a higher incidence of cardiovascular disease and at…
  • Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection

    Janet van Adelsberg1, Steven P. Weinstein2, Neil Graham3, Tanya Momtahen4, Chunpeng Fan5 and Stefano Fiore6, 1Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, 2Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 3Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Program Direction, Sanofi, Bridgewater, NJ, 5Biostatistics, Sanofi, Bridgewater, NJ, 6Clinical Science, Sanofi, Bridgewater, NJ

    Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…
  • Abstract Number: 2353 • 2012 ACR/ARHP Annual Meeting

    TLR2 Activation by Acute Serum Amyloid A Induces Pro-Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis

    Peadar Rooney1, Danielle Molloy1, Jennifer McCormick2, Mary Connolly1, Sinead M. Miggin3, Ashwini Maratha3, Douglas J. Veale4, Conor Murphy5, Eamonn Molloy6 and Ursula Fearon7, 1Rheumatology, Dublin Academic Medical Centre, Dublin, Ireland, 2Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 3Biology, Immune Signalling Laboratory, Maynooth, Ireland, 4Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 5Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, 6Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 7Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis of this disease is characterised by disregulated angiogenesis and inflammatory…
  • Abstract Number: 1794 • 2012 ACR/ARHP Annual Meeting

    Matrix Metalloproteinase 3 and Acute Phase Proteins As Markers of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis

    Mahmood MTM Ally1, Bridget Hodkinson2, Pieter W.A Meyer1, Eustasius Musenge3, Mohammed Tikly4 and Ronald Anderson1, 1University of Pretoria, Pretoria, South Africa, 2Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, 3University of Witwatersrand, Johannesburg, South Africa, 4Rheumatology, Division of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Although matrix metalloproteinase-3 (MMP-3) is believed to be intimately involved in the immunopathogenesis of rheumatoid arthritis (RA), relatively little is known about its relationships…
  • Abstract Number: 245 • 2012 ACR/ARHP Annual Meeting

    Similarities of Patient Self-Report Scores From a Multidimensional Health Assessment Questionnaire (MDHAQ), Laboratory Tests, Physician Global Assessment, and Polyarticular Involvement in Patients with Osteoarthritis and Rheumatoid Arthritis

    Isabel Castrejón1, Yusuf Yazici2 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Rheumatology, NYU Hospital for Joint Diseases, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) and osteoarthritis (OA) are distinct diagnoses, based on widely differing pathogenetic mechanisms and treatments. However, OA patients may experience functional disability,…
  • Abstract Number: 65 • 2012 ACR/ARHP Annual Meeting

    Serum Inflammatory Biomarkers Correlated Stronger with a Panel of Serum Steroid and Pituitary Hormones in a Cohort of Pre-Rheumatoid Arthritis (pre-RA) Than in Non-RA Control (CN) Subjects

    Alfonse T. Masi1, Kevin B. Elmore1, Azeem A. Rehman1, Jean C. Aldag1 and Robert T. Chatterton2, 1Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, 2Obstetrics and Gynecology and Physiology, Northwestern University, Chicago, IL

    Background/Purpose: Inflammatory cytokines influence steroid hormone production in tissue culture and affect serum levels and synovial fluid of active RA patients.  Inflammatory biomarker and hormonal…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology